Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7039-7044

  Hsia, Te Chun ^a,b   Chang, Wen Shin ^b,c   Liang, Shinn Jye ^a,b   Chen, Wei Chun ^a,b   Tu, Chih Yen ^a,b   Chen, Hung Jen ^a   Yang, Mei Due ^b   Tsai, Chia Wen ^b   Hsu, Chin Mu ^b   Tsai, Chang Hai ^b   Bau, Da Tian ^b,c  

^a Department of Internal Medicine ^*  (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Genotype; Interleukin 10; Lung cancer; Polymorphism; Smoking; Taiwan.

Indexed keywords

INTERLEUKIN 10; IL10 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIFESTYLE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; EMBRYOLOGY; EPIDEMIOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; RISK; TAIWAN;

FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK; SMOKING; TAIWAN;

EID: 84918561379     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Shields PG and Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18: 2309-2315, 2000.
2. Shields PG: Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876, 2002.
3. Ji YN, Wang Q and Suo LJ: CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS One 7: e43397, 2012.
4. Spitz MR, Gorlov IP, Dong Q, Wu X, Chen W, Chang DW, Etzel CJ, Caporaso NE, Zhao Y, Christiani DC, Brennan P, Albanes D, Shi J, Thun M, Landi MT and Amos CI: Multistage analysis of variants in the inflammation pathway and lung cancer risk in smokers. Cancer Epidemiol Biomarkers Prev 21: 1213-1221, 2012.
5. Hsia TC, Tsai CW, Liang SJ, Chang WS, Lin LY, Chen WC, Tu CY, Tsai CH and Bau DT: Effects of ataxia telangiectasia mutated (ATM) genotypes and smoking habits on lung cancer risk in Taiwan. Anticancer Res 33: 4067-4071, 2013.
6. Chen WC, Tsai CW, Hsia TC, Chang WS, Lin LY, Liang SJ, Tu CY, Cheng WE, Chen HJ, Wang SM and Bau d T: The contribution of DNA apurinic/apyrimidinic endonuclease genotype and smoking habit to Taiwan lung cancer risk. Anticancer Res 33: 2775-2778, 2013.
7. Liu CJ, Hsia TC, Tsai RY, Sun SS, Wang CH, Lin CC, Tsai CW, Huang CY, Hsu CM and Bau DT: The joint effect of hOGG1 single nucleotide polymorphism and smoking habit on lung cancer in Taiwan. Anticancer Res 30: 4141-4145, 2010.
8. Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, Hang LW, Wang CH, Lee HZ, Tsai RY and Bau DT: Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res 30: 1195-1199, 2010.
9. Govindan R: Lung cancer in never smokers: a new hot area of research. Lancet Oncol 11: 304-305, 2010.
10. Landi MT, Chatterjee N, Caporaso NE, Rotunno M, Albanes D, Thun M, Wheeler W, Rosenberger A, Bickeboller H, Risch A, Wang Y, Gaborieau V, Thorgeirsson T, Gudbjartsson D, Sulem P, Spitz MR, Wichmann HE, Rafnar T, Stefansson K, Houlston RS and Brennan P: GPC5 rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol 11: 714-716; author reply 716, 2010.
11. Liu YL, Xu Y, Li F, Chen H and Guo SL: CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. Tumour Biol 34: 2651-2657, 2013.
12. Lo YL, Hsiao CF, Jou YS, Chang GC, Tsai YH, Su WC, Chen KY, Chen YM, Huang MS, Hsieh WS, Chen CJ and Hsiung CA: Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer 72: 280-286, 2011.
13. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA and Yang P: Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res 73: 4028-4038, 2013.
14. Stearns ME, Rhim J and Wang M: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5: 189-196, 1999.
15. Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, Shete S and Bruera E: The influence of tumor necrosis factor-alpha-308 G/A and IL-6-174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev 17: 3262-3267, 2008.
16. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D and Spitz MR: Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 38: 894-902, 2009.
17. Rausch SM, Gonzalez BD, Clark MM, Patten C, Felten S, Liu H, Li Y, Sloan J and Yang P: SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer 77: 217-223, 2012.
18. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S and Nieters A: Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7: 27-38, 2006.
19. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Kloss M, Gocht D, Potthoff B, Tzvetkov M, Brockmoller J, Loffler M, Pfreundschuh M and Trumper L: Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkins lymphoma: an exploratory study. Clin Cancer Res 14: 3777-3784, 2008.
20. Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, Osterborg A, Bjorkholm M, Holm G, Yi Q and Sundblad A: Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 95: 184-188, 2001.
21. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G, De Maria R and Stassi G: Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 66: 1491-1499, 2006.
22. Cacev T, Radosevic S, Krizanac S and Kapitanovic S: Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29: 1572-1580, 2008.
23. Giacomelli L, Gianni W, Belfiore C, Gandini O, Repetto L, Filippini A, Frati L, Agliano AM and Gazzaniga P: Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clin Cancer Res 9: 2678-2682, 2003.
24. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K and Tangrea JA: Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19: 119-124, 2008.
25. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY and Hayes RB: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66: 4525-4530, 2006.
26. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P and Langsenlehner U: Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119: 701-705, 2010.
27. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML and Wu XT: Interleukin-10-1082 promoter polymorphism associated with gastric cancer among Asians. Eur J Cancer 44: 2648-2654, 2008.
28. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC and Lin LY: The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50: 291-297, 2005.
29. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P and Seifart U: TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21: 157-165, 2005.
30. Hart K, Landvik NE, Lind H, Skaug V, Haugen A and Zienolddiny S: A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of nonsmall cell lung cancer. Lung Cancer 71: 123-129, 2011.
31. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE and Boschetto P: Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30: 627-632, 2007.
32. Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L and Khuri FR: Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 9: 1785-1791, 2003.
33. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK and Khuri FR: Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583, 2004.
34. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E and Catalano G: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373, 2000.
35. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M and Ueyama Y: Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11: 815-819, 2000.
36. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y and Chen H: Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 30: 62, 2011.
37. Montuenga LM and Pio R: Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30: 608-610, 2007.
38. Hsia TC, Liu CJ, Chu CC, Hang LW, Chang WS, Tsai CW, Wu CI, Lien CS, Liao WL, Ho CY and Bau DT: Association of DNA double-strand break gene XRCC6 genotypes and lung cancer in Taiwan. Anticancer Res 32: 1015-1020, 2012.
39. Wang BY, Huang JY, Cheng CY, Lin CH, Ko J and Liaw YP: Lung cancer and prognosis in taiwan: a population-based cancer registry. J Thorac Oncol 8: 1128-1135, 2013.
40. Chang YH, Huang CN, Wu CY and Shiau MY: Association of interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum Immunol 66: 1258-1263, 2005.
41. Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, Chen CY, Shieh SH and Lee H: Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One 7: e39525, 2012.
42. Cesar-Neto JB, Duarte PM, de Oliveira MC, Tambeli CH, Sallum EA and Nociti FH Jr.: Smoking modulates interleukin-6:interleukin-10 and RANKL:osteoprotegerin ratios in the periodontal tissues. J Periodontal Res 42: 184-191, 2007.
43. Mosser DM and Zhang X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226: 205-218, 2008.
44. Saraiva M and OGarra A: The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181, 2010.
45. OGarra A and Vieira P: T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7: 425-428, 2007.
46. Kim R, Emi M, Tanabe K and Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536, 2006.
47. Diaz-Valdes N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JI, Borras-Cuesta F, Sarobe P and Feijoo E: Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 71: 812-821, 2011.